Next Article 
Antimicrobial Agents and Chemotherapy, April 2005, p. 1271-1278, Vol. 49, No. 4
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.4.1271-1278.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Molecular Detection of the Macrolide Efflux Gene: To Discriminate or Not To Discriminate between mef(A) and mef(E)
Corné H. W. Klaassen* and
Johan W. Mouton
Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands

INTRODUCTION
The presence of a novel macrolide efflux system in streptococci
was first described and firmly established in 1996 by Sutcliffe
et al. (
81). This system was phenotypically recognized and characterized
to confer low-level resistance (MICs, 1 to 32 µg/ml) to
14- and 15-membered macrolides but not to 16-membered macrolides,
lincosamides, or streptogramin B (or their analogues). This
phenotypic pattern of antibiotic resistance was referred to
as M-type resistance and is in contrast to the MLS
B phenotype,
which confers constitutive high-level resistance (MICs,

256
µg/ml) to macrolides, lincosamides, as well as streptogramin
B. In the same year Clancy et al. (
16) identified the gene responsible
for this novel efflux system in
Streptococcus pyogenes, and
it was designated
mef(A). This gene was deposited in the public
DNA databases and could be considered the reference sequence
for the
mef(A) gene (GenBank accession number
U70055). Tait-Kamradt
et al. (
84) later identified a similar gene in
Streptococcus pneumoniae that at the time was designated
mef(E). Likewise,
this gene could be considered the reference sequence for
mef(E)
(GenBank accession number
U83667).
The coding sequences of these two genes appeared to share 90% identity at the DNA level (Fig. 1). Remarkably, in contrast to what might be expected due to the degeneracy of the genetic code, they share only 88% identity at the protein level (48 mismatches in a protein of 405 amino acids). The encoded proteins are strongly hydrophobic, apparent integral membrane proteins with 12 transmembrane segments (16). Because of the high degree of similarity between the mef(A) and the mef(E) genes, Roberts et al. (74) suggested in a minireview that both genes be referred to as just a single class, mef(A). The result of this recommendation would be that if there would be a need to discriminate between the two genes, the recommended nomenclature would be something like mef(A) subclass mef(A) to indicate mef(A) and mef(A) subclass mef(E) to indicate mef(E). In order to increase the readability, we prefer to use the original names mef(A) and mef(E) throughout this minireview.
In a number of reports it has since been shown that a number
of marked differences between
mef(A) and
mef(E) exist. For instance,
the genetic elements carrying
mef(A) or
mef(E) and their contexts
have been studied by Santagati et al. (
75), Gay and Stephens
(
29), and Del Grosso et al. (
23) and were shown not only to
be quite different but also to behave quite differently. The
two genes have disseminated markedly differently and are being
recognized in an ever growing number of microbial species. At
present, both the
mef(A) and the
mef(E) genes have unambiguously
been identified in five streptococcal species, whereas
mef(E)
has been identified in five more streptococcal species and in
nine additional nonstreptococcal species (Table
1). Furthermore,
Amezaga et al. (
5) reported that the MICs for
mef(A)-containing
S.
pneumoniae isolates were significantly higher than those
for
mef(E)-containing isolates. This indicates that, despite
the high degree of homology between the two genes, in the context
of the genome in which they are embedded, the differences between
them are sufficient to impose different susceptibility characteristics
on the strains carrying the genes. The existence of these differences
between the two genes has prompted others to suggest that the
difference between the two genes be maintained (
23,
55) and
may have been one reason(s) why others also continued using
the names
mef(A) and
mef(E) after publication of the nomenclature
minireview (
5,
12,
13,
15,
19,
23,
35,
54,
55,
66).
As a result of this, there is no widespread consensus about
the nomenclature for the
mef genes in the present literature.
For readers unaware of this, this may give rise to conflicting
interpretations of the available literature and resources on
the subject. In this minireview, we outline how the use of different
mef gene nomenclatures has created considerable confusion in
the field. We also review the current resources on the subject:
we performed a search for
mef gene sequences in public DNA databases
and looked at methods for the detection of
mef genes in clinical
isolates and tools that can be used to discriminate between
mef(A) and
mef(E). This information was then used to review
the data in the literature with respect to reported genes versus
the actual genes that were studied, given the information in
the methods sections.

mef GENE SEQUENCES IN PUBLIC DNA DATABASES
Macrolide efflux (
mef) genes have been detected in an ever increasing
number of different microbial species. We first investigated
whether or not these genes were identical to the genes originally
detected in
S.
pyogenes and
S.
pneumoniae. For this, a search
of the general public DNA databases for the original
mef(A)
coding sequence (GenBank accession number
U70055; Fig.
1) (
16)
was performed with the BLAST program (
http://www.ncbi.nlm.nih.gov/BLAST/).
This yielded a total of 24
mef-related sequences. All but two
were identified in gram-positive cocci, with the exceptions
being
Neisseria gonorrhoeae and
Bacteroides ovatus. These 24
sequences were deposited in the databases as 9
mef(A) sequences,
5
mef(E) sequences, and 10 sequences identified as macrolide
efflux (
mef) genes without further specification (Table
2).
A DNA sequence alignment of the coding regions was made by using
the ClustalX program (
4) to identify their similarities to the
originally described
mef(A) and
mef(E) genes. The five deposited
mef(E) gene sequences were 100% identical to the originally
described
mef(E) gene sequence (GenBank accession number
U83667)
(
84). However, various nucleotide differences were found among
the sequences that were deposited as
mef(A). It turns out that
only three
mef(A) sequences proved to be 100% identical to the
original
mef(A) gene sequence. Four of nine sequences from gram-positive
organisms deposited as
mef(A) sequences actually proved to be
100% identical to the original
mef(E) sequence. In addition,
the gene from
N.
gonorrhoeae (GenBank accession number
AY319932),
deposited as a
mef(A) gene, turned out to be a
mef(E) gene variant
(>99% identical). The ninth
mef(A)-like sequence identified
in
B.
ovatus proved to be 90% identical to the original
mef(A)
gene sequence and 86% identical to the original
mef(E) gene
sequence. The encoded protein, however, lacks the amino-terminal
29 residues and 66 carboxy-terminal residues found in
mef(A)
and contains only 8 rather than 12 putative transmembrane segments.
Also, no apparent low-level erythromycin resistance could be
attributed to this gene (
88). Therefore, this particular gene
sequence is unlikely to encode an actual macrolide efflux pump.
Thus, of the nine
mef(A) sequences in the public databases,
only three sequences proved to be actual
mef(A) gene sequences.
Because most of these nine
mef(A) sequences were submitted after
publication of the minireview by Roberts et al. (
74), use of
the name
mef(A) in the deposition of these sequences would be
according to the previously recommended nomenclature. However,
this recommendation did not include comments that indicated
if the sequence actually represented the original
mef(A) or
mef(E) sequence, which would have been more appropriate. Both
genes were just considered to be a single class,
mef(A). Of
the 10 gene sequences that were deposited as being a
mef gene
without further specification, the sequences of 4 genes (identified
in
Granulicatella adiacens isolates and
Gemella haemolysans)
were 100% identical to that of
mef(E), whereas the sequence
of 1 (from a group G
Streptococcus) was >99% identical to
the original
mef(A) sequence. The remaining five
mef sequences
(all from group G streptococci) represent novel
mef genes or
variants. Two of these five are both 96% identical to
mef(E)
and 90% identical to
mef(A) (GenBank accession numbers
AY355405 and
AY355406). The remaining three (GenBank accession numbers
AY355408,
AY355409, and
AY355410) are all 90% identical to
mef(E),
88% identical to
mef(A), and 90% identical to the two sequences
with GenBank accession numbers
AY355405 and
AY355406. Since
these novel
mef genes have only recently been published, they
fall beyond the scope of this minireview.
Because only three of nine
mef(A) sequences in the public DNA
databases proved to be actual
mef(A) gene sequences, we conclude
that the use of public databases as a sole resource for
mef(A)
gene sequences may result in the use of improper reference sequences.
This may have contributed to the current confusion about the
mef gene nomenclature.

DNA-BASED DETECTION OF THE mef GENES IN CLINICAL ISOLATES
Several techniques for the detection of the
mef genes in clinical
isolates have been described. However, in the large majority
of the studies in the literature examined (73 of 77 articles,
excluding fundamental publications on the subject), detection
of
mef gene sequences by molecular biology-based methods is
performed by PCR as either the primary or secondary screening
procedure. In the remaining studies, some form of DNA hybridization
assay was performed (for instance, dot blotting or microwell
hybridization assays).
It is not much of a surprise to find that PCR is by far the most established method for the detection of mef genes. No less than 14 different PCR primer combinations for amplification of the mef gene have been reported up to now, and these create amplification products ranging from 202 to 1,759 bp (Table 3). To a certain extent it makes perfect sense to use different PCR primer combinations for amplification of the same gene. In this way one might circumvent the pitfall of not being able to amplify incidental variants of the mef gene carrying a point mutation in the primer-specific region. Unfortunately, not all primer combinations appear to be equally suitable for amplification of the mef genes. In no less than 9 of these 14 PCR primer combinations, the sequences of either or both the forward and the reverse primer do not match both target sequences equally well due to the presence of a mismatch between the primer sequence and one of the two target sequences. If this mismatch is located near the 5' end of the primer or several residues away from the 3' end of the primer, this will probably not affect amplification of either or both mef genes. However, in several cases the mismatch(es) is located at the ultimate 3' end of the primer sequence or multiple mismatches are present along the sequence of the primer(s). In theory, the use of such primers may result in an inefficient PCR, leading to the preferential amplification of the mef gene without the mismatch. In this context, it is entirely conceivable that in the studies in which the primer combination of Oster et al. (62) has been used (19, 62), only the mef(A) gene was reported (as confirmed by restriction enzyme analysis; see below). Likewise, by use of the primer combination of Ono et al. (60), only the mef(E) gene was reported (although this was not confirmed). Interestingly, the primer combination reported by Amezaga et al. (5) in combination with regular Taq DNA polymerase would, in theory, be specific for the mef(E) gene but reportedly amplified both mef(A) and mef(E) (as confirmed by DNA sequence analysis). It is noteworthy that in many studies PCR-based assays were used with selected isolates following a prescreening by use of the erythromycin or the clindamycin MIC. The use of a single PCR primer combination or the use of suboptimal primer pairs may explain why sometimes no explanation for resistance to macrolides could be found (although we cannot ignore the possibility that this could also have been the result of the presence of other known determinants [but which were not tested for] or even yet unknown macrolide resistance determinants). Fortunately, however, the large majority of studies used PCR primer combinations that were able to amplify both mef(A) and mef(E) (Table 3).

TOOLS TO DISCRIMINATE BETWEEN mef(A) AND mef(E)
After having established the presence of
mef genes in clinical
isolates, the ability to discriminate between
mef(A) and
mef(E)
naturally depends on the techniques and assays used. The high
degree of similarity between the two genes does not allow a
reliable discrimination to be made by using DNA hybridization
experiments. Unless the probe is meticulously designed, any
probe based on the
mef(A) gene sequence will also hybridize
to the
mef(E) gene, even under high-stringency conditions, and
vice versa. In contrast, DNA sequence analysis may yield the
ultimate means of discrimination between
mef(A) and
mef(E) (and
may even identify point mutations and novel
mef-related genes),
provided that the proper reference sequences are being used
for comparison. In this respect, it should be needless to mention
that the accuracies of the DNA sequences deposited in the public
libraries are of crucial importance. Here, however, a potential
problem arises in the case of
mef(A) (see above). The most straightforward
method for discrimination between
mef(A) and
mef(E) is based
on the differential presence of restriction enzyme recognition
sites in the two genes. A simple digest with a number of restriction
enzymes followed by agarose gel electrophoresis should be sufficient
to establish the difference. For all of the 14 PCR primer combinations
described in Table
3, multiple restriction enzyme recognition
sites exist to discriminate between
mef(A) and
mef(E), which
allows the easy dissemination of such an approach. Unfortunately,
only only a few groups have applied this approach. A minor caveat
to the use of this method is the incidental occurrence of point
mutations in the
mef gene that could destroy existing restriction
enzyme recognition sites or create additional restriction enzyme
recognition sites. The occurrence of point mutations in both
the
mef(A) and the
mef(E) genes have been mentioned in several
publications (
10,
66,
84). The use of more than one restriction
enzyme for the identification of each gene may circumvent this
pitfall and might even allow recognition of such mutations.
As far as is known, this has not led to erroneous conclusions.
Furthermore, a real-time PCR assay for the identification of
mef genes and discrimination between
mef(A) and
mef(E) has recently
been described by Klomberg et al. (
41). This assay enables the
even easier discrimination between the two. In conclusion, simple
techniques can establish the difference between
mef(A) and
mef(E).

REVIEW OF LITERATURE DATA: GENES REPORTED VERSUS GENES ANALYZED
In light of the information presented above, the existing literature
was reviewed with respect to the subject of the study according
to the authors and what the actual subject of the study was
according to the methods used:
mef(A) or
mef(E), or both (the
studies are summarized in Table
4). Unfortunately, discrimination
between
mef(A) and
mef(E) was properly established (either by
restriction enzyme digestion or by DNA sequence analysis of
the PCR amplicons obtained) in only 14 of 77 (18%) publications.
In 53 publications, only a PCR was performed to detect the
mef gene. In an additional six cases, a PCR was combined with some
form of DNA hybridization assay (like a dot blot, Southern blot,
or microwell hybridization assay). In four more cases, only
a DNA hybridization assay was performed. Consequently, as highlighted
in Table
4, in a total of 63 of 77 (82%) publications reviewed,
mef(A) and
mef(E) could not be discriminated on the basis of
the methods used. This is properly acknowledged in 13 cases,
in which the target of the assay is generally referred to as
either
mef or
mef(A/E). In the remaining 50 publications, the
subject of study is claimed to be either the
mef(A) gene or
the
mef(E) gene, with no effort undertaken to discriminate between
the two genes. As mentioned above, in a small number of cases
(
5,
7,
46,
47,
56,
66,
82) this was done in good faith with
reference to the aforementioned recommendation by Roberts et
al. (
74). In the majority of other studies that reportedly dealt
with
mef(A), there was no specific reference to the paper by
Roberts et al. (
74), nor was it apparent from the context that
the authors were aware of the nomenclature recommendation. Furthermore,
in a number of cases it was assumed that when
S.
pneumoniae isolates were studied, it must have involved the
mef(E) gene
(since this gene was first described in
S.
pneumoniae). Correspondingly,
when
S.
pyogenes isolates were studied, the gene involved was
assumed to have been the
mef(A) gene. However, we now know that
both the
mef(A) and the
mef(E) genes are present in
S.
pneumoniae as well as in
S.
pyogenes and that these working assumptions
were actually incorrect. Thus, in the large majority of the
publications in which
mef(A) or
mef(E) only is mentioned, the
mef gene detected might just as well have been the other
mef gene or even both genes. Interestingly, in six publications,
a biphasic MIC distribution was obtained for isolates carrying
only a
mef gene and no other gene or mechanism that would result
in macrolide resistance (
21,
32,
37,
54,
59,
87). This indicates
that the collection of strains under investigation may have
contained two distinct variants of macrolide efflux genes. This
observation nicely fits the observed different antibiotic resistance
levels for isolates carrying
mef(A) and
mef(E) (
5). In those
studies, the populations of strains investigated may very well
have contained both
mef(A) and
mef(E). The isolates for which
the MICs were lower may have been carrying
mef(E), whereas the
isolates for which the MICs were higher may have been carrying
mef(A). As a consequence of this, in 82% of the articles in
the literature examined, it is confusing, to say the least,
whether the actual subject of the publication was
mef(A) or
mef(E), or both. However, Table
3 provides a convenient means
to review these aspects of the available literature.
View this table:
[in this window]
[in a new window]
|
TABLE 4. Overview of literature data on detection of mef genes and the ability to discriminate between mef(A) and mef(E)a
|
Although Amezaga et al. (
5) yielded statistically significant
data about the differences in the MICs for strains carrying
mef(A) and
mef(E); and even though this finding was later confirmed
by Neeleman et al. (C. Neeleman, C. H. W. Klaassen, H. A. de
Valk, and J. W. Mouton, Abstr. 43rd Intersci. Conf. Antimicrob.
Agents Chemother., abstr. C2-68, 2003), it has also been reported
that almost all
S.
pneumoniae isolates confirmed to be carrying
mef(A) appear to be highly clonally related (
5,
23). This places
the MIC differences in an uncertain light, so more work clearly
needs to be done to address this issue. Ideally, this could
be investigated by inserting the
mef(A) and
mef(E) genes in
an identical defined genetic background. Alternatively, more
clonally unrelated strains carrying
mef(A) should be tested.

CONCLUSIONS AND RECOMMENDATIONS
Ongoing insight into the properties of the
mef genes now acts
in favor for maintenance of the difference between
mef(A) and
mef(E). This does not mean that in certain studies it could
be of only minor relevance to determine if a macrolide resistance
gene actually represents
mef(A) or
mef(E). Much of the current
confusion about the
mef gene nomenclature can be resolved by
making the distinction after all. If it had not been for those
who took the effort to distinguish between
mef(A) and
mef(E),
we would not have known about the marked differences between
them. Furthermore, as outlined above, simple procedures can
be used to determine whether one is dealing with
mef(A) or
mef(E),
so it should be easy to establish the difference. In this respect,
we must also reflect on the 1999 nomenclature recommendation
by Roberts et al. (
74). If we were to continue using the nomenclature
as suggested, we would be dealing with
mef(A) subclass
mef(A)
and
mef(A) subclass
mef(E). Not only does this look rather awkward,
but more groups already tend to use the original names,
mef(A)
and
mef(E), or use the common name
mef instead of following
the previously recommended nomenclature suggestion. Although
at the time it made sense to suggest a common name for both
genes, in retrospect it may be concluded that it has been rather
misfortunate to suggest the name
mef(A) for both genes instead
of the more common name
mef. By using the common name
mef(A)
for all
mef genes, much of the current confusion will continue.
However, by using the name
mef, it is immediately apparent to
the reader that no efforts were made to discriminate between
mef(A),
mef(E) as well as future other variants. Therefore,
it makes sense to refer to these genes as just
mef in a general
context or as
mef(A) or
mef(E) and other new variants only when
appropriate assays have been performed to establish the difference.

FOOTNOTES
* Corresponding author. Mailing address: Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen 6532 SZ, The Netherlands. Phone: 31-24-3657514. Fax: 31-24-3657516. E-mail:
c.klaassen{at}cwz.nl.


REFERENCES
1 - Acikgoz, Z. C., S. Gocer, and S. Tuncer. 2003. Macrolide resistance determinants of group A streptococci in Ankara, Turkey. J. Antimicrob. Chemother. 52:110-112.[Abstract/Free Full Text]
2 - Akata, F., D. Ozturk, O. Tansel, M. Tatman-Otkun, M. Otkun, F. Fitoussi, E. Bingen, and M. Tugrul. 2002. Resistance to macrolides in group A streptococci from the European section of Turkey: genetic and phenotypic characterization. Int. J. Antimicrob. Agents 20:461-463.[Medline]
3 - Alos, J. I., B. Aracil, J. Oteo, C. Torres, J. L. Gomez-Garces, and the Spanish Group for the Study of Infection in the Primary Health Care Setting. 2000. High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. J. Antimicrob. Chemother. 45:605-609.[Abstract/Free Full Text]
4 - Altschul, S. F., T. L. Madden, A. A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D. J. Lipman. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389-3402.[Abstract/Free Full Text]
5 - Amezaga, M. R., P. E. Carter, P. Cash, and H. McKenzie. 2002. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J. Clin. Microbiol. 40:3313-3318.[Abstract/Free Full Text]
6 - Angot, P., M. Vergnaud, M. Auzou, and R. Leclercq. 2000. Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae. Observatoire de Normandie du Pneumocoque. Eur. J. Clin. Microbiol. Infect. Dis. 19:755-758.[Medline]
7 - Aracil, B., M. Minambres, J. Oteo, C. Torres, J. L. Gomez-Garces, and J. I. Alos. 2001. High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J. Antimicrob. Chemother. 48:592-594.[Free Full Text]
8 - Arpin, C., M.-H. Canron, J. Maugein, and C. Quentin. 1999. Incidence of mef(A) and mef(E) genes in viridans group streptococci. Antimicrob. Agents Chemother. 43:2335-2336.[Free Full Text]
9 - Arpin, C., M.-H. Canron, P. Noury, and C. Quentin. 1999. Emergence of mef(A) and mef(E) genes in beta-haemolytic streptococci and pneumococci in France. J. Antimicrob. Chemother. 44:133-134.[Free Full Text]
10 - Arpin, C., H. Daube, F. Tessier, and C. Quentin. 1999. Presence of mef(A) and mef(E) genes in Streptococcus agalactiae. Antimicrob. Agents Chemother. 43:944-946.[Abstract/Free Full Text]
11 - Bemer-Melchior, P., M.-E. Juvin, S. Tassin, A. Bryskier, G. C. Schito, and H.-B. Drugeon. 2000. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob. Agents Chemother. 44:2999-3002.[Abstract/Free Full Text]
12 - Bingen, E., F. Fitoussi, C. Doit, R. Cohen, A. Tanna, R. George, C. Loukil, N. Brahimi, I. Le Thomas, and D. Deforche. 2000. Resistance to macrolides in Streptococcus pyogenes in France in pediatric patients. Antimicrob. Agents Chemother. 44:1453-1457.[Abstract/Free Full Text]
13 - Bingen, E., R. Leclercq, F. Fitoussi, N. Brahimi, B. Malbruny, D. Deforche, and R. Cohen. 2002. Emergence of group A Streptococcus strains with different mechanisms of macrolide resistance. Antimicrob. Agents Chemother. 46:1199-1203.[Abstract/Free Full Text]
14 - Brandt, C. M., M. Honscha, N. D. Truong, R. Holland, B. Hovener, A. Bryskier, R. Lutticken, and R. R. Reinert. 2001. Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany. Microb. Drug Resist. 7:165-170.[CrossRef][Medline]
15 - Cascone, C., M. Santagati, S. Noviello, F. Iannelli, S. Esposito, G. Pozzi, and S. Stefani. 2002. Macrolide-resistance genes in clinical isolates of Streptococcus pyogenes. Microb. Drug Resist. 8:129-132.[CrossRef][Medline]
16 - Clancy, J., J. Petitpas, F. Dib-Hajj, W. Yuan, M. Cronan, A. V. Kamath, J. Bergeron, and J. A. Retsema. 1996. Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mef(A), from Streptococcus pyogenes. Mol. Microbiol. 22:867-879.[CrossRef][Medline]
17 - Corso, A., E. P. Severina, V. F. Petruk, Y. R. Mauriz, and A. Tomasz. 1998. Molecular characterization of penicillin-resistant Streptococcus pneumoniae isolates causing respiratory disease in the United States. Microb. Drug Resist. 4:325-337.[Medline]
18 - Cousin, S., Jr., W. L. H. Whittington, and M. C. Roberts. 2003. Acquired macrolide resistance genes in pathogenic Neisseria spp. isolated between 1940 and 1987. Antimicrob. Agents Chemother. 47:3877-3880.[Abstract/Free Full Text]
19 - Cresti, S., M. Lattanzi, A. Zanchi, F. Montagnani, S. Pollini, C. Cellesi, and G. M. Rossolini. 2002. Resistance determinants and clonal diversity in group A streptococci collected during a period of increasing macrolide resistance. Antimicrob. Agents Chemother. 46:1816-1822.[Abstract/Free Full Text]
20 - Culebras, E., I. Rodriguez-Avial, C. Betriu, M. Redondo, and J. J. Picazo. 2002. Macrolide and tetracycline resistance and molecular relationships of clinical strains of Streptococcus agalactiae. Antimicrob. Agents Chemother. 46:1574-1576.[Abstract/Free Full Text]
21 - de Azavedo, J. C. S., M. McGavin, C. Duncan, D. E. Low, and A. McGeer. 2001. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B Streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 45:3504-3508.[Abstract/Free Full Text]
22 - de Azavedo, J. C. S., R. H. Yeung, D. J. Bast, C. L. Duncan, S. B. Borgia, and D. E. Low. 1999. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob. Agents Chemother. 43:2144-2147.[Abstract/Free Full Text]
23 - Del Grosso, M., F. Iannelli, C. Messina, M. Santagati, N. Petrosillo, S. Stefani, G. Pozzi, and A. Pantosti. 2002. Macrolide efflux genes mef(A) and mef(E) are carried by different genetic elements in Streptococcus pneumoniae. J. Clin. Microbiol. 40:774-778.[Abstract/Free Full Text]
24 - Descheemaeker, P., S. Chapelle, C. Lammens, M. Hauchecorne, M. Wijdooghe, P. Vandamme, M. Ieven, and H. Goossens. 2000. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J. Antimicrob. Chemother. 45:167-173.[Abstract/Free Full Text]
25 - d'Oliveira, R. E., R. R. Barros, C. R. Mendonca, L. M. Teixeira, and A. C. Castro. 2003. Antimicrobial susceptibility and survey of macrolide resistance mechanisms among Streptococcus pyogenes isolated in Rio de Janeiro, Brazil. Microb. Drug Resist. 9:87-91.[CrossRef][Medline]
26 - Facinelli, B., C. Spinaci, G. Magi, E. Giovanetti, and P. Varaldo. 2001. Association between erythromycin resistance and ability to enter human respiratory cells in group A streptococci. Lancet 358:30-33.[CrossRef][Medline]
27 - Farrell, D. J., I. Morrissey, S. Bakker, and D. Felmingham. 2001. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J. Antimicrob. Chemother. 48:541-544.[Abstract/Free Full Text]
28 - Fitoussi, F., C. Doit, P. Geslin, N. Brahimi, and E. Bingen. 2001. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob. Agents Chemother. 45:636-638.[Abstract/Free Full Text]
29 - Gay, K., and D. S. Stephens. 2001. Structure and dissemination of a chromosomal insertion element encoding macrolide efflux in Streptococcus pneumoniae. J. Infect. Dis. 184:56-65.[CrossRef][Medline]
30 - Giovanetti, E., A. Brenciani, R. Lupidi, M. C. Roberts, and P. E. Varaldo. 2003. Presence of the tet(O) gene in erythromycin- and tetracycline-resistant strains of Streptococcus pyogenes and linkage with either the mef(A) or the erm(A) gene. Antimicrob. Agents Chemother. 47:2844-2849.[Abstract/Free Full Text]
31 - Giovanetti, E., M. P. Montanari, M. Mingoia, and P. E. Varaldo. 1999. Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity of inducibly resistant strains. Antimicrob. Agents Chemother. 43:1935-1940.[Abstract/Free Full Text]
32 - Hoban, D. J., A. K. Wierzbowski, K. Nichol, and G. G. Zhanel. 2001. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob. Agents Chemother. 45:2147-2150.[Abstract/Free Full Text]
33 - Hoshino, K., H. Watanabe, R. Sugita, N. Asoh, S. A. Ntabaguzi, K. Watanabe, K. Oishi, and T. Nagatake. 2002. High rate of transmission of penicillin-resistant Streptococcus pneumoniae between parents and children. J. Clin. Microbiol. 40:4357-4359.[Abstract/Free Full Text]
34 - Hsueh, P.-R., L.-J. Teng, C.-M. Lee, W.-K. Huang, T.-L. Wu, J.-H. Wan, D. Yang, J.-M. Shyr, Y.-C. Chuang, J.-J. Yan, J.-J. Lu, J.-J. Wu, W.-C. Ko, F.-Y. Chang, Y.-C. Yang, Y.-J. Lau, Y.-C. Liu, H.-S. Leu, C.-Y. Liu, and K.-T. Luh. 2003. Telithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 data. Antimicrob. Agents Chemother. 47:2152-2157.[Abstract/Free Full Text]
35 - Jacobs, J. A., G. J. van Baar, N. H. H. J. London, J. H. T. Tjhie, L. M. Schouls, and E. E. Stobberingh. 2001. Prevalence of macrolide resistance genes in clinical isolates of the Streptococcus anginosus ("S. milleri") group. Antimicrob. Agents Chemother. 45:2375-2377.[Abstract/Free Full Text]
36 - Jasir, A., A. Tanna, A. Efstratiou, and C. Schalen. 2001. Unusual occurrence of M type 77, antibiotic-resistant group A streptococci in southern Sweden. J. Clin. Microbiol. 39:586-590.[Abstract/Free Full Text]
37 - Johnston, N. J., J. C. de Azavedo, J. D. Kellner, and D. E. Low. 1998. Prevalence and characterization of the mechanisms of macrolide, lincosamide, and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2425-2426.[Abstract/Free Full Text]
38 - Kataja, J., P. Huovinen, M. Skurnik, the Finnish Study Group for Antimicrobial Resistance, and H. Seppala. 1999. Erythromycin resistance genes in group A streptococci in Finland. Antimicrob. Agents Chemother. 43:48-52.[Abstract/Free Full Text]
39 - Kataja, J., P. Huovinen, The Macrolide Resistance Study Group, and H. Seppala. 2000. Erythromycin resistance genes in group A streptococci of different geographical origins. J. Antimicrob. Chemother. 46:789-792.[Abstract/Free Full Text]
40 - Kataja, J., H. Seppala, M. Skurnik, H. Sarkkinen, and P. Huovinen. 1998. Different erythromycin resistance mechanisms in group C and group G streptococci. Antimicrob. Agents Chemother. 42:1493-1494.[Abstract/Free Full Text]
41 - Klomberg, D. M., H. A. de Valk, J. W. Mouton, and C. H. W. Klaassen. 2005. Rapid and reliable real-time PCR assay for detection of the macrolide efflux gene and subsequent discrimination between its distinct subclasses mef(A) and mef(E). J. Microbiol. Methods 60:269-273.[CrossRef][Medline]
42 - Lagrou, K., W. E. Peetermans, J. Verhaegen, S. Van Lierde, L. Verbist, and J. Van Eldere. 2000. Macrolide resistance in Belgian Streptococcus pneumoniae. J. Antimicrob. Chemother. 45:119-121.[Abstract/Free Full Text]
43 - Latini, L., M. P. Ronchetti, R. Merolla, F. Guglielmi, S. Bajaksouzian, M. P. Villa, M. R. Jacobs, and R. Ronchetti. 1999. Prevalence of mef(E), erm and tet(M) genes in Streptococcus pneumoniae strains from central Italy. Int. J. Antimicrob. Agents 13:29-33.[CrossRef][Medline]
44 - Lim, J.-A., A.-R. Kwon, S.-K. Kim, Y. Chong, K. Lee, and E.-C. Choi. 2002. Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in gram-positive cocci isolated in a Korean hospital. J. Antimicrob. Chemother. 49:489-495.[Abstract/Free Full Text]
45 - Luna, V. A., P. Coates, E. A. Eady, J. H. Cove, T. T. H. Nguyen, and M. C. Roberts. 1999. A variety of gram-positive bacteria carry mobile mef genes. J. Antimicrob. Chemother. 44:19-25.[Abstract/Free Full Text]
46 - Luna, V. A., M. Heiken, K. Judge, C. Ulep, N. Van Kirk, H. Luis, M. Bernardo, J. Leitao, and M. C. Roberts. 2002. Distribution of mef(A) in gram-positive bacteria from healthy Portuguese children. Antimicrob. Agents Chemother. 46:2513-2517.[Abstract/Free Full Text]
47 - Marchandin, H., H. Jean-Pierre, E. Jumas-Bilak, L. Isson, B. Drouillard, H. Darbas, and C. Carriere. 2001. Distribution of macrolide resistance genes erm(B) and mef(A) among 160 penicillin-intermediate clinical isolates of Streptococcus pneumoniae isolated in southern France. Pathol. Biol. (Paris) 49:522-527.[Medline]
48 - Marchese, A., M. Ramirez, G. C. Schito, and A. Tomasz. 1998. Molecular epidemiology of penicillin-resistant Streptococcus pneumoniae isolates recovered in Italy from 1993 to 1996. J. Clin. Microbiol. 36:2944-2949.[Abstract/Free Full Text]
49 - Marchese, A., E. Tonoli, E. A. Debbia, and G. C. Schito. 1999. Macrolide resistance mechanisms and expression of phenotypes among Streptococcus pneumoniae circulating in Italy. J. Antimicrob. Chemother. 44:461-464.[Abstract/Free Full Text]
50 - Marimon, J. M., L. Iglesias, D. Vicente, and E. Perez-Trallero. 2003. Molecular characterization of erythromycin-resistant clinical isolates of the four major antimicrobial-resistant Spanish clones of Streptococcus pneumoniae (Spain23F-1, Spain6B-2, Spain9V-3, and Spain14-5). Microb. Drug Resist. 9:133-137.[CrossRef][Medline]
51 - McGee, L., K. P. Klugman, A. Wasas, T. Capper, A. Brink, and The Antibiotics Surveillance Forum of South Africa. 2001. Serotype 19F multiresistant pneumococcal clone harboring two erythromycin resistance determinants [erm(B) and mef(A)] in South Africa. Antimicrob. Agents Chemother. 45:1595-1598.[Abstract/Free Full Text]
52 - McGee, L., H. Wang, A. Wasas, R. Huebner, M. Chen, and K. P. Klugman. 2001. Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. Microb. Drug Resist. 7:55-63.[CrossRef][Medline]
53 - McKenzie, H., N. Reid, and R. S. Dijkhuizen. 2000. Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteraemia. J. Med. Microbiol. 49:361-366.[Abstract/Free Full Text]
54 - Montanari, M. P., I. Cochetti, M. Mingoia, and P. E. Varaldo. 2003. Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47:2236-2241.[Abstract/Free Full Text]
55 - Montanari, M. P., M. Mingoia, I. Cochetti, and P. E. Varaldo. 2003. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J. Clin. Microbiol. 41:428-431.[Abstract/Free Full Text]
56 - Morosini, M.-I., R. Canton, E. Loza, R. del Campo, F. Almaraz, and F. Baquero. 2003. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J. Antimicrob. Chemother. 52:50-55.[Abstract/Free Full Text]
57 - Nagai, K., Y. Shibasaki, K. Hasegawa, T. A. Davies, M. R. Jacobs, K. Ubukata, and P. C. Appelbaum. 2001. Evaluation of PCR primers to screen for Streptococcus pneumoniae isolates and ß-lactam resistance, and to detect common macrolide resistance determinants. J. Antimicrob. Chemother. 48:915-918.[Abstract/Free Full Text]
58 - Nishijima, T., Y. Saito, A. Aoki, M. Toriya, Y. Toyonaga, and R. Fujii. 1999. Distribution of mef(E) and erm(B) genes in macrolide-resistant strains of Streptococcus pneumoniae and their variable susceptibility to various antibiotics. J. Antimicrob. Chemother. 43:637-643.[Abstract/Free Full Text]
59 - Okamoto, H., K. Tateda, Y. Ishii, T. Matsumoto, T. Kobayashi, S. Miyazaki, and K. Yamaguchi. 2002. High frequency of erythromycin A resistance and distribution of mef(E) and erm(B) genes in clinical isolates of Streptococcus pneumoniae in Japan. J. Infect. Chemother. 8:28-32.[Medline]
60 - Ono, T., S. Shiota, K. Hirota, K. Nemoto, T. Tsuchiya, and Y. Miyake. 2000. Susceptibilities of oral and nasal isolates of Streptococcus mitis and Streptococcus oralis to macrolides and PCR detection of resistance genes. Antimicrob. Agents Chemother. 44:1078-1080.[Abstract/Free Full Text]
61 - Orden, B., E. Perez-Trallero, M. Montes, and R. Martinez. 1998. Erythromycin resistance of Streptococcus pyogenes in Madrid. Pediatr. Infect. Dis. J. 17:470-473.[CrossRef][Medline]
62 - Oster, P., A. Zanchi, S. Cresti, M. Lattanzi, F. Montagnani, C. Cellesi, and G. M. Rossolini. 1999. Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates. Antimicrob. Agents Chemother. 43:2510-2512.[Abstract/Free Full Text]
63 - Palavecino, E. L., I. Riedel, C. Duran, S. Bajaksouzian, M. Joloba, T. Davies, P. C. Appelbaum, and M. R. Jacobs. 2002. Macrolide resistance phenotypes in Streptococcus pneumoniae in Santiago, Chile. Int. J. Antimicrob. Agents 20:108-112.[Medline]
64 - Perez-Trallero, E., J. M. Marimon, M. Montes, B. Orden, and M. de Pablos. 1999. Clonal differences among erythromycin-resistant Streptococcus pyogenes in Spain. Emerg. Infect. Dis. 5:235-240.[Medline]
65 - Perez-Trallero, E., M. Urbieta, M. Montes, I. Ayestaran, and J. M. Marimon. 1998. Emergence of Streptococcus pyogenes strains resistant to erythromycin in Gipuzkoa, Spain. Eur. J. Clin. Microbiol. Infect. Dis. 17:25-31.[CrossRef][Medline]
66 - Perez-Trallero, E., D. Vicente, M. Montes, J. M. Marimon, and L. Pineiro. 2001. High proportion of pharyngeal carriers of commensal streptococci resistant to erythromycin in Spanish adults. J. Antimicrob. Chemother. 48:225-229.[Abstract/Free Full Text]
67 - Petinaki, E., F. Kontos, A. Pratti, C. Skulabis, and A. N. Maniatis. 2003. Clinical isolates of macrolide-resistant Streptococcus pyogenes in central Greece. Int. J. Antimicrob. Agents 21:67-70.[CrossRef][Medline]
68 - Pihlajamaki, M., J. Jalava, P. Huovinen, and P. Kotilainen. 2003. Antimicrobial resistance of invasive pneumococci in Finland in 1999-2000. Antimicrob. Agents Chemother. 47:1832-1835.[Abstract/Free Full Text]
69 - Pihlajamaki, M., T. Kaijalainen, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistance. 2002. Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000. J. Antimicrob. Chemother. 49:785-792.[Abstract/Free Full Text]
70 - Portillo, A., M. Lantero, M. J. Gastanares, F. Ruiz-Larrea, and C. Torres. 1999. Macrolide resistance phenotypes and mechanisms of resistance in Streptococcus pyogenes in La Rioja, Spain. Int. J. Antimicrob. Agents 13:137-140.[CrossRef][Medline]
71 - Portillo, A., F. Ruiz-Larrea, M. Zarazaga, A. Alonso, J. L. Martinez, and C. Torres. 2000. Macrolide resistance genes in Enterococcus spp. Antimicrob. Agents Chemother. 44:967-971.[Abstract/Free Full Text]
72 - Poutanen, S. M., J. de Azavedo, B. M. Willey, D. E. Low, and K. S. MacDonald. 1999. Molecular characterization of multidrug resistance in Streptococcus mitis. Antimicrob. Agents Chemother. 43:1505-1507.[Abstract/Free Full Text]
73 - Poyart, C., L. Jardy, G. Quesne, P. Berche, and P. Trieu-Cuot. 2003. Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob. Agents Chemother. 47:794-797.[Abstract/Free Full Text]
74 - Roberts, M. C., J. Sutcliffe, P. Courvalin, L. B. Jensen, J. Rood, and H. Seppala. 1999. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob. Agents Chemother. 43:2823-2830.[Free Full Text]
75 - Santagati, M., F. Iannelli, M. R. Oggioni, S. Stefani, and G. Pozzi. 2000. Characterization of a genetic element carrying the macrolide efflux gene mef(A) in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2585-2587.[Abstract/Free Full Text]
76 - Seppala, H., M. Haanpera, M. Al-Juhaish, H. Jarvinen, J. Jalava, and P. Huovinen. 2003. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J. Antimicrob. Chemother. 52:636-644.[Abstract/Free Full Text]
77 - Seral, C., F. J. Castillo, M. C. Rubio-Calvo, A. Fenoll, C. Garcia, and R. Gomez-Lus. 2001. Distribution of resistance genes tet(M), aph3'-III, catpC194 and the integrase gene of Tn1545 in clinical Streptococcus pneumoniae harbouring erm(B) and mef(A) genes in Spain. J. Antimicrob. Chemother. 47:863-866.[Abstract/Free Full Text]
78 - Shortridge, V. D., G. V. Doern, A. B. Brueggemann, J. M. Beyer, and R. K. Flamm. 1999. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin. Infect. Dis. 29:1186-1188.[CrossRef][Medline]
79 - Stadler, C., and M. Teuber. 2002. The macrolide efflux genetic assembly of Streptococcus pneumoniae is present in erythromycin-resistant Streptococcus salivarius. Antimicrob. Agents Chemother. 46:3690-3691.[Free Full Text]
80 - Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40:2562-2566.[Abstract]
81 - Sutcliffe, J., A. Tait-Kamradt, and L. Wondrack. 1996. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob. Agents Chemother. 40:1817-1824.[Abstract]
82 - Syrogiannopoulos, G. A., I. N. Grivea, T. A. Davies, G. D. Katopodis, P. C. Appelbaum, and N. G. Beratis. 2000. Antimicrobial use and colonization with erythromycin-resistant Streptococcus pneumoniae in Greece during the first 2 years of life. Clin. Infect. Dis. 31:887-893.[CrossRef][Medline]
83 - Syrogiannopoulos, G. A., I. N. Grivea, F. Fitoussi, C. Doit, G. D. Katopodis, E. Bingen, and N. G. Beratis. 2001. High prevalence of erythromycin resistance of Streptococcus pyogenes in Greek children. Pediatr. Infect. Dis. J. 20:863-868.[CrossRef][Medline]
84 - Tait-Kamradt, A., J. Clancy, M. Cronan, F. Dib-Hajj, L. Wondrack, W. Yuan, and J. Sutcliffe. 1997. mef(E) is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:2251-2255.[Abstract]
85 - Ubukata, K., S. Iwata, and K. Sunakawa. 2003. In vitro activities of new ketolide, telithromycin, and eight other macrolide antibiotics against Streptococcus pneumoniae having mef(A) and erm(B) genes that mediate macrolide resistance. J. Infect. Chemother. 9:221-226.[CrossRef][Medline]
86 - Valisena, S., C. Falci, A. Mazzariol, G. Cornaglia, C. E. Cocuzza, P. Nicoletti, R. Rescaldani, and R. Fontana. 1999. Molecular typing of erythromycin-resistant Streptococcus pyogenes strains with the M phenotype isolated in Italy. Eur. J. Clin. Microbiol. Infect. Dis. 18:260-264.[CrossRef][Medline]
87 - Waites, K., C. Johnson, B. Gray, K. Edwards, M. Crain, and W. Benjamin, Jr. 2000. Use of clindamycin disks to detect macrolide resistance mediated by erm(B) and mef(E) in Streptococcus pneumoniae isolates from adults and children. J. Clin. Microbiol. 38:1731-1734.[Abstract/Free Full Text]
88 - Wang, Y., G.-R. Wang, A. Shelby, N. B. Shoemaker, and A. A. Salyers. 2003. A newly discovered Bacteroides conjugative transposon, CTnGERM1, contains genes also found in gram-positive bacteria. Appl. Environ. Microbiol. 69:4595-4603.[Abstract/Free Full Text]
89 - Weber, P., J. Filipecki, E. Bingen, F. Fitoussi, G. Goldfarb, J. P. Chauvin, C. Reitz, and H. Portier. 2001. Genetic and phenotypic characterization of macrolide resistance in group A streptococci isolated from adults with pharyngo-tonsillitis in France. J. Antimicrob. Chemother. 48:291-294.[Abstract/Free Full Text]
90 - Weiss, K., J. De Azavedo, C. Restieri, L. A. Galarneau, M. Gourdeau, P. Harvey, J. F. Paradis, K. Salim, and D. E. Low. 2001. Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. J. Antimicrob. Chemother. 47:345-348.[Abstract/Free Full Text]
91 - Widdowson, C. A., and K. P. Klugman. 1998. Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa. Emerg. Infect. Dis. 4:277-281.[Medline]
92 - Woo, P. C. Y., A. P. C. To, H. Tse, S. K. P. Lau, and K.-Y. Yuen. 2003. Clinical and molecular epidemiology of erythromycin-resistant beta-hemolytic Lancefield group G streptococci causing bacteremia. J. Clin. Microbiol. 41:5188-5191.[Abstract/Free Full Text]
93 - Yan, J.-J., H.-M. Wu, A.-H. Huang, H.-M. Fu, C.-T. Lee, and J.-J. Wu. 2000. Prevalence of polyclonal mef(A)-containing isolates among erythromycin-resistant group A streptococci in southern Taiwan. J. Clin. Microbiol. 38:2475-2479.[Abstract/Free Full Text]
Antimicrobial Agents and Chemotherapy, April 2005, p. 1271-1278, Vol. 49, No. 4
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.4.1271-1278.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Blackman Northwood, J., Del Grosso, M., Cossins, L. R., Coley, M. D., Creti, R., Pantosti, A., Farrell, D. J.
(2009). Characterization of Macrolide Efflux Pump mef Subclasses Detected in Clinical Isolates of Streptococcus pyogenes Isolated between 1999 and 2005. Antimicrob. Agents Chemother.
53: 1921-1925
[Abstract]
[Full Text]
-
Varaldo, P. E., Montanari, M. P., Giovanetti, E.
(2009). Genetic Elements Responsible for Erythromycin Resistance in Streptococci. Antimicrob. Agents Chemother.
53: 343-353
[Full Text]
-
Domelier, A.-S., van der Mee-Marquet, N., Arnault, L., Mereghetti, L., Lanotte, P., Rosenau, A., Lartigue, M.-F., Quentin, R.
(2008). Molecular characterization of erythromycin-resistant Streptococcus agalactiae strains. J Antimicrob Chemother
62: 1227-1233
[Abstract]
[Full Text]
-
Cai, Y., Kong, F., Gilbert, G. L.
(2007). Three New Macrolide Efflux (mef) Gene Variants in Streptococcus agalactiae. J. Clin. Microbiol.
45: 2754-2755
[Full Text]
-
Hawkyard, C. V., Koerner, R. J.
(2007). The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. J Antimicrob Chemother
59: 347-358
[Abstract]
[Full Text]
-
Ardanuy, C., Fenoll, A., Berron, S., Calatayud, L., Linares, J., the Spanish Pneumococcal Infection Study Network,
(2006). Increase of the M Phenotype among Erythromycin-Resistant Streptococcus pneumoniae Isolates from Spain Related to the Serotype 14 Variant of the Spain9V-3 Clone.. Antimicrob. Agents Chemother.
50: 3162-3165
[Abstract]
[Full Text]
-
Ojo, K. K., Ruehlen, N. L., Close, N. S., Luis, H., Bernardo, M., Leitao, J., Roberts, M. C.
(2006). The presence of a conjugative Gram-positive Tn2009 in Gram-negative commensal bacteria. J Antimicrob Chemother
57: 1065-1069
[Abstract]
[Full Text]
-
Amezaga, M. R., McKenzie, H.
(2006). Molecular epidemiology of macrolide resistance in {beta}-haemolytic streptococci of Lancefield groups A, B, C and G and evidence for a new mef element in group G streptococci that carries allelic variants of mef and msr(D). J Antimicrob Chemother
57: 443-449
[Abstract]
[Full Text]
-
Zeng, X., Kong, F., Wang, H., Darbar, A., Gilbert, G. L.
(2006). Simultaneous Detection of Nine Antibiotic Resistance-Related Genes in Streptococcus agalactiae Using Multiplex PCR and Reverse Line Blot Hybridization Assay. Antimicrob. Agents Chemother.
50: 204-209
[Abstract]
[Full Text]
-
Cochetti, I., Vecchi, M., Mingoia, M., Tili, E., Catania, M. R., Manzin, A., Varaldo, P. E., Montanari, M. P.
(2005). Molecular Characterization of Pneumococci with Efflux-Mediated Erythromycin Resistance and Identification of a Novel mef Gene Subclass, mef(I). Antimicrob. Agents Chemother.
49: 4999-5006
[Abstract]
[Full Text]
-
Wierzbowski, A. K., Boyd, D., Mulvey, M., Hoban, D. J., Zhanel, G. G.
(2005). Expression of the mef(E) Gene Encoding the Macrolide Efflux Pump Protein Increases in Streptococcus pneumoniae with Increasing Resistance to Macrolides. Antimicrob. Agents Chemother.
49: 4635-4640
[Abstract]
[Full Text]
-
Sangvik, M., Littauer, P., Simonsen, G. S., Sundsfjord, A., Dahl, K. H.
(2005). mef(A), mef(E) and a new mef allele in macrolide-resistant Streptococcus spp. isolates from Norway. J Antimicrob Chemother
56: 841-846
[Abstract]
[Full Text]
-
Tamayo, J., Perez-Trallero, E., Gomez-Garces, J. L., Alos, J. I., on behalf of the Spanish Group for the Study of In,
(2005). Resistance to macrolides, clindamycin and telithromycin in Streptococcus pyogenes isolated in Spain during 2004. J Antimicrob Chemother
56: 780-782
[Abstract]
[Full Text]
-
Poole, K.
(2005). Efflux-mediated antimicrobial resistance. J Antimicrob Chemother
56: 20-51
[Abstract]
[Full Text]